latest on TAS-102

Thanks steve. It's good to have more choices, perhaps another backbone chemo.

Notice how the best results, 50% response vs less than 10% alone (Steve's 2nd link), were obtained with combined therapies.  Multimodulated combos are the key to preventing and breaking through resistance.  This is where mild off label drugs and targeted supplements have such great add on possibilities, and are available now.  When the proven medicine is out of proven medicines, this is where necessity drives new combos.

coloCan said:

A multi-pronged approach,attacking several pathways or

molecules/proteins/genes is,it seems,the way to go. But which ones? I've come across so many different proteins/genes,etc that researchers have studied and concluded that they have a "major" or "crucial" impact on CRC and mets . For instance we've all heard of KRAS or BRAF and maybe even PIK3CA but what about PLAC8,SATB1,PIK3R3,CNDP2......I could fill your screen with the names of genes/proteins/molecules said to pertain to CRC that has been published by researchers  somewhere on this planet. Aiming for pathways, of which there are much fewer,such as Wnt,Notch,Hedgehog,might be more viable. VEGF and EGFR have been  major targets (Avastin,Vectibix,erbitux)......I find it utterly amazing how scientists can look at a piece of tissue from our body and differentiate one molecule/gene/protein from another--yet this is so vitally important.....One practical aspect of this can be read here:

www.onclive.com/conference-coverage/world-GI-2014/Dr-Peeters-Discusses-the-Frequency-of-S492R-mutations-in-Patients-with-mCRC

(This may be a useful site to check weekly for those into reading this type of material) 

 

 

 

Many target proteins have 5-6, even a dozen, published names over time and research locations.  Many identified proteins occur along a pathway.  The only realistic way to modulate many targets simultaneously is through natural compounds - both for cost (often bulk components cost cents per day) and far less side effects on a massive array of targets.  More than a few pharma treatments at a time, and human body functions pretty much disintegrate.  

We keep it simple on the pharma cide with daily, low dose UFT-LV, roughly like xeloda but nicer, with some advantages on comfort, reliability of metabolism and antimetastasis. And cost (too nice and too cheap for US FDA approval). Then cimetidine, and more recently celcoxib, on prescription generics.  After that, selectable supernutrient supplements that probably modulate/target almost everything to one degree or another.  We provide diverse but eclectic ammo, to largely let the body sort and target the molecules after that.